Pay vs Performance Disclosure
|
12 Months Ended |
|
Oct. 31, 2025
USD ($)
|
Oct. 31, 2024
USD ($)
|
Oct. 31, 2023
USD ($)
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Disclosure - Pay vs Performance Disclosure |
|
| Year |
|
|
Table
Total for
PEO (1)
|
|
|
Paid
to
PEO (2)
|
|
|
Table
Total for Non-PEO
NEOs (1)
|
|
|
Paid
to Non-PEO
NEOs (2)
|
|
|
TSR
(3)
|
|
|
Peer
Group
TSR (3)
|
|
|
Net
Loss
(millions) (4)
|
|
|
Company
Selected
Measure (5)
|
|
| |
|
|
Summary
Compensation |
|
|
Compensation
Actually |
|
|
Average Summary
Compensation |
|
|
Average Compensation Actually |
|
|
Value of Initial
Fixed $100
Investment
Based On (3): |
|
|
|
|
|
|
|
| Year |
|
|
Table
Total for
PEO (1) |
|
|
Paid
to
PEO (2) |
|
|
Table
Total for Non-PEO
NEOs (1) |
|
|
Paid
to Non-PEO
NEOs (2) |
|
|
TSR |
|
|
Peer Group
TSR |
|
|
Net Loss
(millions) (4) |
|
|
Company
Selected
Measure (5) |
|
| 2025 |
|
|
$ |
2,546,684 |
|
|
$ |
3,708,818 |
|
|
$ |
1,298,705 |
|
|
$ |
1,630,653 |
|
|
$ |
73.75 |
|
|
$ |
137.23 |
|
|
$ |
11.0 |
|
|
|
- |
|
| 2024 |
|
|
$ |
3,476,037 |
|
|
$ |
3,129,297 |
|
|
$ |
1,760,002 |
|
|
$ |
1,493,234 |
|
|
$ |
62.50 |
|
|
$ |
118.14 |
|
|
$ |
12.7 |
|
|
|
- |
|
| 2023 |
|
|
$ |
3,639,651 |
|
|
$ |
(2,620,710 |
) |
|
$ |
1,965,876 |
|
|
$ |
134,096 |
|
|
$ |
56.43 |
|
|
$ |
80.63 |
|
|
$ |
9.9 |
|
|
|
- |
|
|
|
|
| Named Executive Officers, Footnote [Text Block] |
|
| (1) |
For
each fiscal year presented, Dr. Kumar was our Principal Executive Officer (“PEO”) and Mr. Catelani was our only Non-PEO
NEO. |
| (2) |
The
CAP amounts presented reflect the following adjustments to compensation reported within the Summary Compensation Table as required
by the SEC: |
| (3) |
Total
Shareholder Return (“TSR”) represents cumulative total shareholder return on a fixed investment of $100 in our common
stock for the period beginning on the last trading day of the fiscal year ended October 31, 2022 through the last trading day of
the applicable fiscal year. Peer Group TSR represents cumulative total shareholder return on a fixed investment of $100 in the S&P
Biotechnology Select Industry Index for the period beginning on the last trading day of the fiscal year ended October 31, 2022 through
the last trading day of the applicable fiscal year. |
| (4) |
The
dollar amounts reported represent the amount of net loss reflected in our audited financial statements for the applicable year. While
we are a pre-revenue biotechnology company and no portion of NEO compensation is dependent upon our net loss, SEC rules require that
net income/loss be presented as a performance measure in this table. |
| (5) |
As
a pre-revenue biotechnology company, we have implemented a business model that conserves funds by collaborating with third parties
to develop our technologies. As a result, at this stage in our corporate life-cycle, there is no single financial performance measure
that our Compensation Committee uses when considering annual compensation for our NEOs. Instead, the Compensation Committee focuses
on a variety of factors including the progress of development of our various technologies, our level of operating expenses and our
cash position. After discussion with our Compensation Committee, and given the relative weight that the Compensation Committee affords
each of these factors and our unique business model, we have elected not to include a “Company-Selected Measure” at this
time. We will continue to assess this decision in consultation with our Compensation Committee on a forward looking basis and will
include a “Company-Selected Measure” when our Compensation Committee deems it appropriate. |
|
|
|
| PEO Total Compensation Amount |
[1] |
$ 2,546,684
|
$ 3,476,037
|
$ 3,639,651
|
| PEO Actually Paid Compensation Amount |
[2] |
3,708,818
|
3,129,297
|
(2,620,710)
|
| Non-PEO NEO Average Total Compensation Amount |
[1] |
1,298,705
|
1,760,002
|
1,965,876
|
| Non-PEO NEO Average Compensation Actually Paid Amount |
[2] |
$ 1,630,653
|
1,493,234
|
134,096
|
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |
|
|
(2)
|
The
CAP amounts presented reflect the following adjustments to compensation reported within the Summary Compensation Table as required
by the SEC: |
| |
|
2025 |
|
|
2024 |
|
|
2023 |
|
| Adjustments to Summary Compensation Table amounts to CAP amounts |
|
PEO |
|
|
Average
Non-PEO
NEOs |
|
|
PEO |
|
|
Average
Non-PEO
NEOs |
|
|
PEO |
|
|
Average
Non-PEO
NEOs |
|
| Summary Compensation Table |
|
$ |
2,546,684 |
|
|
$ |
1,298,705 |
|
|
$ |
3,476,037 |
|
|
$ |
1,760,002 |
|
|
$ |
3,639,651 |
|
|
$ |
1,965,876 |
|
| Grant Date FV of option awards granted in fiscal year |
|
|
(1,129,100 |
) |
|
|
(564,550 |
) |
|
|
(2,093,000 |
) |
|
|
(1,046,500 |
) |
|
|
(2,354,100 |
) |
|
|
(1,177,050 |
) |
| FV at year-end of outstanding and unvested option awards granted in fiscal year |
|
|
1,562,686 |
|
|
|
781,343 |
|
|
|
1,104,143 |
|
|
|
552,072 |
|
|
|
1,013,134 |
|
|
|
506,567 |
|
| Vesting date FV of awards granted in fiscal year and vested in fiscal year |
|
|
433,436 |
|
|
|
216,718 |
|
|
|
385,700 |
|
|
|
192,850 |
|
|
|
510,047 |
|
|
|
255,024 |
|
| Change in FV of awards granted in prior years that are outstanding and unvested as of the end of the fiscal year |
|
|
562,023 |
|
|
|
53,087 |
|
|
|
244,489 |
|
|
|
25,943 |
|
|
|
(4,284,013 |
) |
|
|
(926,354 |
) |
| Change in FV of awards granted in prior years and vested in fiscal year |
|
|
(266,911 |
) |
|
|
(154,650 |
) |
|
|
11,928 |
|
|
|
8,867 |
|
|
|
(1,145,429 |
) |
|
|
(489,967 |
) |
| Total Compensation Actually Paid |
|
$ |
3,708,818 |
|
|
$ |
1,630,653 |
|
|
$ |
3,129,297 |
|
|
$ |
1,493,234 |
|
|
$ |
(2,620,710 |
) |
|
$ |
134,096 |
|
|
|
|
| Equity Valuation Assumption Difference, Footnote [Text Block] |
|
| (3) |
Total
Shareholder Return (“TSR”) represents cumulative total shareholder return on a fixed investment of $100 in our common
stock for the period beginning on the last trading day of the fiscal year ended October 31, 2022 through the last trading day of
the applicable fiscal year. Peer Group TSR represents cumulative total shareholder return on a fixed investment of $100 in the S&P
Biotechnology Select Industry Index for the period beginning on the last trading day of the fiscal year ended October 31, 2022 through
the last trading day of the applicable fiscal year. |
|
|
|
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] |
|
Chart
1: Compensation Actually Paid versus TSR
|
|
|
| Chart 2: Compensation Actually Paid versus Net Loss |
|
Chart
2: Compensation Actually Paid versus Net Loss
|
|
|
| Total Shareholder Return Amount |
[3] |
$ 73.75
|
62.50
|
56.43
|
| Peer Group Total Shareholder Return Amount |
[3] |
137.23
|
118.14
|
80.63
|
| Net Income (Loss) Attributable to Parent |
[4] |
$ 11,000,000.0
|
$ 12,700,000
|
$ 9,900,000
|
| Company Selected Measure Amount |
[5] |
|
|
|
| PEO Name |
|
Dr. Kumar
|
Dr. Kumar
|
Dr. Kumar
|
| Additional 402(v) Disclosure [Text Block] |
|
| (4) |
The
dollar amounts reported represent the amount of net loss reflected in our audited financial statements for the applicable year. While
we are a pre-revenue biotechnology company and no portion of NEO compensation is dependent upon our net loss, SEC rules require that
net income/loss be presented as a performance measure in this table. |
|
|
|
| Grant Date FV of Option Awards Granted in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
$ (1,129,100)
|
$ (2,093,000)
|
$ (2,354,100)
|
| Grant Date FV of Option Awards Granted in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
(564,550)
|
(1,046,500)
|
(1,177,050)
|
| FV at Year-end of Outstanding and Unvested Option Awards Granted in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
1,562,686
|
1,104,143
|
1,013,134
|
| FV at Year-end of Outstanding and Unvested Option Awards Granted in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
781,343
|
552,072
|
506,567
|
| Vesting date FV of Awards Granted in Fiscal Year and Vested in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
433,436
|
385,700
|
510,047
|
| Vesting date FV of Awards Granted in Fiscal Year and Vested in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
216,718
|
192,850
|
255,024
|
| Change in FV of Awards Granted in Prior Years that are Outstanding and Unvested as of the End of the Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
562,023
|
244,489
|
(4,284,013)
|
| Change in FV of Awards Granted in Prior Years that are Outstanding and Unvested as of the End of the Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
53,087
|
25,943
|
(926,354)
|
| Change in FV of Awards Granted in Prior Years and Vested in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
(266,911)
|
11,928
|
(1,145,429)
|
| Change in FV of Awards Granted in Prior Years and Vested in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
$ (154,650)
|
$ 8,867
|
$ (489,967)
|
|
|